Piccart M J, Speyer J L, Markman M, ten Bokkel Huinink W W, Alberts D, Jenkins J, Muggia F
Semin Oncol. 1985 Sep;12(3 Suppl 4):90-6.
With the rapid expansion of research programs examining intraperitoneal chemotherapy for ovarian cancer and other intraabdominal malignancies, there is a need for a reliable and safe access to the peritoneal cavity. The technical experience accumulated with either the Tenckhoff catheter or the Port-A-Cath in 288 patients treated at five institutions showed a low incidence of catheter-related peritonitis (5% and 8%, respectively), skin infection (6.6% and 0%), and bowel perforation following surgical implantation (3.5% and 1.3%). Postoperative leakage of intraabdominal fluid, bleeding, or ileus were uncommon and easily controlled. Drainage failure was the major problem with both systems; occurring in 45% of patients. Although both systems are workable, improved catheters for the administration of intraperitoneal chemotherapy are warranted.
随着针对卵巢癌及其他腹腔内恶性肿瘤的腹腔内化疗研究项目迅速扩展，需要一种可靠且安全的进入腹腔的途径。在五家机构接受治疗的288例患者中，使用Tenckhoff导管或植入式静脉输液港积累的技术经验显示，导管相关腹膜炎的发生率较低（分别为5%和8%），皮肤感染发生率分别为6.6%和0%，手术植入后肠穿孔发生率分别为3.5%和1.3%。腹腔内液体术后渗漏、出血或肠梗阻并不常见且易于控制。引流失败是这两种系统的主要问题，在45%的患者中发生。尽管这两种系统都可行，但仍需要改进用于腹腔内化疗给药的导管。
